After taking enough doses of Anamorelin, do you need to continue taking it for life?

Anamorelin (Anamorelin) is an oral motilin/growth hormone secretagogue (ghrelin) receptor agonist. It is mainly used to improve cancer-related cachexia (such as weight loss, decreased appetite and muscle loss in patients with advanced lung cancer, pancreatic cancer, etc.). Its mechanism of action is to promote appetite, increase weight and muscle mass by activating ghrelin receptors, thereby improving the patient's overall nutritional status and quality of life. Because of its rapid onset of action and good safety, it is used in many countries to help improve the physical fitness and nutrition of cancer patients.

Although anamorelin can significantly improve appetite and weight in the short term, it does not have to be taken for life. The treatment cycle should be flexibly adjusted according to the patient's disease stage and treatment goals. Clinically, after most patients recover their weight and improve their nutritional status, doctors will decide whether to stop taking or reduce the dosage based on the assessment. Some patients whose weight is stable or whose disease is in remission can gradually stop taking the drug, while those who are still in a state of persistent cachexia may need to maintain it for a longer period of time.

It should be noted that the efficacy of anamorelin depends on continued use. Once the drug is discontinued, its improvement in appetite and weight may gradually weaken. Therefore, whether to use it for a long time or repeatedly needs to be comprehensively judged by the doctor based on the actual situation of the patient. If you experience weight loss, loss of appetite, or physical weakness after stopping the medication, your doctor may recommend restarting the medication.

In general, anamorelin is not a type of drug that requires "lifelong use". It is more like a staged, goal-oriented supportive treatment tool. During the treatment period, multidisciplinary collaboration such as nutritional intervention, anti-tumor treatment, and exercise rehabilitation should be combined to formulate an individualized medication plan. Anamorelin should be continued to be used only under clear medical indications to avoid abuse or dependence while safeguarding the patient's long-term health management goals.

Reference materials:https://www.drugs.com/